logo
Temenos survey reveals banks doubling down on technology modernization to drive customer experience

Temenos survey reveals banks doubling down on technology modernization to drive customer experience

Yahoo22-05-2025

Despite economic and geopolitical uncertainty banks are investing in technology with clear focus on customer experience, protection and innovation
MADRID, Spain, May 22, 2025 (GLOBE NEWSWIRE) -- At the Temenos Community Forum '25 in Madrid, Temenos, a global leader in banking technology, shared insights from a global study by Hanover Research of 424 business and technology leaders in financial services that underscores a bold shift in banking priorities.
The research shows financial institutions are accelerating investments in technology, and placing customer experience, innovation, and operational efficiency at the top of their strategic agendas. Investing in technology to improve customer experience emerged as the top strategic priority for 46% of banks worldwide, followed closely by the launch of new products and services (35%), and the pursuit of greater operational efficiency (34%).
In the face of rapid geopolitical changes, banks need to modernize to be able to predict, understand and adapt rapidly to market changes; capabilities their legacy systems are not equipped to deliver. To meet these demands, (77%) of financial institutions are investing in data analytics and AI-driven insights and 68% in cloud-based core banking systems, all while maintaining a strong focus on protecting both themselves and their customers as a priority.
Amid the turbulence of inflation, tariffs and trade tensions, most banks anticipate they will increase investment in technology to better protect customers (84%) and technology to enhance operational efficiency (81%). In addition, three quarters of banks plan to increase their investments to improve systems integration (75%) and data analytics (73%).
Most professionals (81%) agree that if banks do not implement artificial intelligence they will fall behind competitors. While only 11% of banks have fully implemented generative AI today, 43% are in the process, indicating more than half are moving forward with real deployment. Notably, 60% of banking professionals view AI as a tool to augment, not replace the human workforce.
In her plenary keynote at TCF, Isabelle Guis, Chief Marketing Officer, Temenos, said: 'The message is clear: while banks continue to invest in modernization, they're doing so with a close eye on evolving market dynamics. Financial institutions understand that staying competitive means being ready to adapt and there's a growing recognition that failing to embrace AI soon could leave them behind.'
The study results pertaining to AI and Gen AI were discussed on a recent webinar with Jerry Silva, Program Vice President, IDC, Maya Mikhailov, Founder and Chief Executive Officer, Savvi AI and Isabelle Guis, Chief Marketing Officer at Temenos (link).
About the research
Conducted by Hanover Research in April 2025, the survey captured insights from 424 senior banking executives across retail, commercial, credit union, and wealth management sectors. All respondents held director-level or higher roles in IT or business functions overseeing products, services, or strategy. The survey had a global reach, with participants from North America (47%), Europe (24%), the Middle East & Africa (17%), Latin America (6%), and Australia/New Zealand (6%).
CONTACT: Scott Rowe Temenos + 44 (0) 20 7423 3857 scott.rowe@temenos.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Nyanzaga Gold Project Technical Report
Nyanzaga Gold Project Technical Report

Yahoo

timean hour ago

  • Yahoo

Nyanzaga Gold Project Technical Report

Perth, June 10, 2025 (GLOBE NEWSWIRE) -- PERSEUS RELEASES TECHNICAL REPORT FOR THE NYANZAGA GOLD PROJECT Perth, Western Australia/June 10, 2025/ Perseus Mining Limited (ASX/TSX: PRU) is pleased to announce the release of the Technical Report for its Nyanzaga Gold Project (NGP) in Tanzania. The Technical Report, with an effective date of April 28, 2025, was prepared in compliance with Canadian Securities Administrators' National Instrument 43-101 and is available on and The Report summarises the results of the updated Feasibility Study to demonstrate the technical and economic viability of the NGP and supports a decision to advance to development. Please refer to News Release dated April 28, 2025 'Perseus Mining proceeds with development of the Nyanzaga Gold Project' for a summary of the material information contained in the Nyanzaga Technical Report. This announcement was approved for release by the Managing Director & CEO, Jeff Quartermaine. ASX/TSX CODE: PRUCAPITAL STRUCTURE:Ordinary shares: 1,362,221,512Performance rights: 10,056,681REGISTERED OFFICE:Level 2437 Roberts RoadSubiaco WA 6008Telephone: +61 8 6144 DIRECTORS:Rick MenellNon-Executive ChairmanJeff QuartermaineManaging Director & CEO Amber BanfieldNon-Executive DirectorElissa CorneliusNon-Executive DirectorDan LougherNon-Executive DirectorJohn McGloinNon-Executive Director CONTACTS:Jeff QuartermaineManaging Director & FormanInvestor Relations+61 484 036 RyanMedia Relations+61 420 582

Tredence Wins Fourth Consecutive Databricks Retail and CPG Partner of the Year Award at Data + AI Summit
Tredence Wins Fourth Consecutive Databricks Retail and CPG Partner of the Year Award at Data + AI Summit

Yahoo

time2 hours ago

  • Yahoo

Tredence Wins Fourth Consecutive Databricks Retail and CPG Partner of the Year Award at Data + AI Summit

Trusted by 8 of the top 10 retailers and CPGs and recognized for driving last mile AI impact by modernizing data, industrializing GenAI, and scaling AI. SAN FRANCISCO, June 10, 2025 /PRNewswire/ -- Tredence, a global data science and AI solutions company, today announced that it has been named the Databricks Retail & CPG (RCG) Partner of the Year for the fourth consecutive year. Tredence was selected for their standout expertise in harnessing the Databricks Data Intelligence Platform and deep domain expertise to drive exceptional value for retail and CPG clients. Presented at the annual Databricks Data + AI Summit, the award celebrates Tredence's exceptional contributions to modernizing data and AI infrastructure, accelerating GenAI implementation, and scaling AI adoption across some of the world's largest retailers and consumer brands, collectively generating over $2T in global revenue. Over the past year, Tredence has demonstrated an unparalleled commitment to helping Retail and CPG enterprise organizations build data intelligence through its collaboration with Databricks, the Data and AI company. "Tredence is the AI expert driving the Data & AI strategy for 8 of the top 10 global retailers. Together with Databricks, we're helping industry leaders modernize their data foundations, enhance governance, and operationalize GenAI," said Morgan Seybert, President and Chief Business Officer of Retail at Tredence. "Backed by our unified retail data model, 150+ AI/ML accelerators, and 12+ GenAI agents, we're solving complex data science and data engineering challenges at scale." "In CPG, speed and precision drives growth. We help brands unlock growth by bridging the gap between insight and action—using Agentic AI, predictive forecasting and connected data to optimize every shelf, in every market," said Sagar Balan, Chief Business Officer of CPG at Tredence. "Our collaboration with Databricks is helping CPG leaders turn insights into immediate business impact. This is where data stops being passive and starts delivering value that compounds." In FY25, Tredence and Databricks helped leading retail and CPG enterprises drive business value across three core areas: Modernization that delivers: Unlocked $220M EBITA, $13M in labor savings, and a 10%+ improvement in forecast accuracy for a leading grocery chain in the U.S. Monetization through intelligent activation: Enabled $58M+ in retail media network revenue, reduced platform licensing costs by 30–50%, and achieved 3–5X acceleration in time-to-insight for marketing and CX teams for a major American retailer. Industrialization of AI and GenAI: Scaled enterprise-wide GenAI leading to 3X faster adoption, 30% productivity boost, 100% compliance for a leading CPG enterprise. "Tredence continues to push the boundaries of how data and AI unlock value for our joint clients in retail and CPG," said Matt Jackson, Vice President of Sales, Retail & Consumer Goods at Databricks. "Their focus on last-mile analytics impact, coupled with a powerful library of Brickbuilder Solutions, is helping RCGs move faster—from data to decision." Adding to this honor, Tredence was also awarded the Databricks Growth Partner of the Year for the Americas, reaffirming its position as the trusted Data & AI partner to leading enterprises across the region. About Tredence Tredence is a global data science and AI solutions provider focused on solving the last-mile problem in AI – the gap between insight creation and value realization. Tredence leverages deep domain expertise, data platforms and accelerators, and strategic partnerships to provide targeted, impactful solutions to its clients. The company has 3,500+ employees across San Francisco Bay Area, Chicago, London, Toronto, and Bengaluru, serving top brands in Retail, CPG, Hi-tech, Telecom, Healthcare, Travel, and Industrials. For more information, visit and follow us on LinkedIn. Photo: View original content: Sign in to access your portfolio

RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program
RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program

Yahoo

time2 hours ago

  • Yahoo

RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program

BENGALURU, India, June 09, 2025 (GLOBE NEWSWIRE) -- RenaissThera Private Limited ('RenaissThera'), a Bengaluru-based biotechnology company, announced a major milestone in its obesity drug discovery program targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). GIPR, an incretin receptor, is a validated target for peptide-based parenteral therapies where both stimulation and inhibition has shown efficacy in treating obesity and its co-morbidities. RenaissThera is developing novel, oral small molecules, both agonists and antagonists, as a more affordable and convenient alternative aiming to expand access for underserved populations in the global obesity market projected to reach USD 38 billion by 2032. Oral small molecules are more economical to manufacture and distribute than peptide-based obesity drugs. These molecules were designed and screened using proprietary AI and ML based platforms, followed by demonstrating in-vitro activity in cell lines and in-vivo activity to impact GIPR in mice to yield 'Hits'. RenaissThera now is advancing these Hits to the Lead optimization program to select candidates for pre-IND studies. RenaissThera is filing 'Composition of Matter' and utility patents for these oral novel small molecule GIPR modulators and continues to expand its innovation portfolio targeting GIP, GLP-1, and apelin receptors in obesity and diabetes. Its AI-powered Innovation Platform, integrating GenAI and machine learning tools, is accelerating the design and optimization of novel small molecules. 'We are grateful to our investors and collaborators for supporting us in reaching this milestone. Our team is focused on pushing candidates toward IND-readiness next year and we are in active discussions with potential pharma partners and investors interested in our obesity program,' said Meena, MD, CEO of RenaissThera. RenaissThera's progress was enabled through its collaboration with VedTechBio Research Private Limited which enabled access to its Agentic AI platform RxAgentAI and discovery expertise. 'We are very pleased with the outcomes of our collaboration with RenaissThera. This milestone further validates our platform and capabilities across key therapeutic areas including obesity, Type 2 diabetes, oncology, and inflammation,' said VedTechBio's Managing Director Sudhir Nagarajan. About RenaissThera RenaissThera is a Bengaluru-based biotech company developing affordable, AI-powered novel small-molecule therapies for high-unmet-need diseases like obesity and diabetes. Its goal is to innovate for underserved populations and expand global access to novel therapies. It leverages India's CRO ecosystem for early-stage R&D to deliver globally relevant innovation. For more information Please contact: Media: Lakshmi Ramakrishna lramakrishna@ Investor & Partnership: Ramkesh Meena bd@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store